Year: 2018

BrainStorm Issues 2018 Letter to Shareholders

From Startup Brainstorm Cell Therapeutics Link to Full Article: NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders. Dear Valued Shareholder, This past year was an extraordinary success for

BrainStorm Expands Manufacturing of NurOwn® for Phase 2 Progressive MS Trial

From Startup Brainstorm Cell Therapeutics Link to Full Article: BrainStorm has contracted with the Connell and O’Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute, currently supporting the Phase 3 ALS Trial, to Produce NurOwn® NEW YORK and BOSTON, Dec. 26, 2018 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics

Xynomic Pharma Acquires Global Exclusive Rights to Phase 2 Ready mTORC1/2 Inhibitor from Boehringer Ingelheim

From Startup Xynomic Pharma Link to Full Article:   Dec 20, 2018, 10:52 ET DOVER, Del. and SHANGHAI, Dec. 20, 2018 /PRNewswire/ — Xynomic Pharmaceuticals, Inc. (“Xynomic”), a clinical stage US-China oncology drug development company, today announced that it has been granted an exclusive, worldwide license to develop, manufacture and commercialize BI 860585,

Precision BioSciences Appoints Rare Disease Executive Shalini Sharp to Its Board of Directors

From Startup Precision Biosciences Link to Full Article: DURHAM, North Carolina, USA, December 19, 2018 – Precision BioSciences, a genome editing company dedicated to improving life, announced today that industry veteran Shalini Sharp has joined the company’s Board of Directors. An established business leader in the life sciences industry,

Lexington, Mass. – December 20, 2018 –

From Startup Kaleido Link to Full Article: Lexington, Mass. – December 20, 2018 – Kaleido Biosciences, a healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ, today announced the appointment of three new members to its Board of Directors: Bonnie Bassler, Ph.D., Chair,

Myovant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference

From Startup Myovant Link to Full Article: BASEL, Switzerland, Dec. 20, 2018 /PRNewswire/ — Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women’s health and endocrine diseases, today announced that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the 37th Annual J.P. Morgan